Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05162898
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05083208
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 1979
- Registration Number
- NCT05063136
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05023720
- Locations
- 🇨🇳
Henan cancer hosiptal, Zhengzhou, Henan, China
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT05013697
- Locations
- 🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳AnYang Tumor Hospital, Anyang, Henan, China
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04948125
- Locations
- 🇨🇳
Henan cancer hospital/The affiliated Cancer Hospital of ZhengZhou university, Henan, China
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04938297
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT04901754
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Not Applicable
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT04891900
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04891016
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2024. All Rights Reserved by MedPath